NCT03389451View on ClinicalTrials.gov

68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 16, 2018

Primary Completion Date

July 23, 2019

Study Completion Date

July 23, 2019

Conditions
Prostate CancerProstatic NeoplasmProstatic Neoplasms, Castration-ResistantProstatic Cancer RecurrentProstatic Cancer Metastatic
Interventions
DRUG

Ga-68 PSMA-HBED-CC PET

Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.

Trial Locations (1)

52242

The University of Iowa Hospitals & Clinics, Iowa City

All Listed Sponsors
collaborator

University of Iowa

OTHER

collaborator

Holden Comprehensive Cancer Center

OTHER

lead

Michael Graham PhD, MD

OTHER

NCT03389451 - 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer | Biotech Hunter | Biotech Hunter